Allogene hints at allogeneic CAR T durability with ALLO-510A data

Allogene is making a durability case for its most advanced CAR T cell program amid rising doubts that off-the-shelf cancer cell therapies will be able to generate the long-term, curative effects seen with autologous products.

During an R&D presentation from Allogene Therapeutics Inc. (NASDAQ:ALLO), the company reported updated data from ALLO-501A, an autologous CAR T cell therapy targeting CD19, demonstrating complete responses lasting more than two years in patients with large B cell lymphoma. ...